Dendreon rockets on unexpected high growth 4Q Provenge sales
This article was originally published in Scrip
Executive Summary
Dendreon, which took a beating during much of 2011, rang in 2012 with unexpectedly high fourth-quarter sales of its prostate cancer immunotherapy Provenge (sipuleucel-T) – nearly tripling figures from a year earlier – which had investors reveling in the good news.